ObjectiveHealth

In case you missed it, we’ve recently announced our collaboration with QualDerm Partners! Clinical research is now integrated into Qualderm's 158 practices, offering innovative care to more than 1.5M patients each year. Learn more about our partnership here: https://yhoo.it/3xMsVkZ

Extraordinary Pursuits Podcast from BIP Ventures recently published an episode featuring Colleen Hoke, Co-founder and CEO of ObjectiveHealth. In their latest episode, Colleen discusses her journey in clinical research, ObjectiveHealth’s innovative approach to democratizing access to clinical trials, and the critical role our partnerships with healthcare providers play in advancing patient care. Learn more about how we're transforming the landscape of clinical research and healthcare here: https://lnkd.in/eAnAYQ9R

The diversity gap in clinical trials is a growing issue, with only 24% of participants from diverse backgrounds. In our latest article, hear from Dr. Raja Din, MD, on how this lack of representation affects patient outcomes and steps to ensure more inclusive trials, here: https://bit.ly/4cLuEpx

ObjectiveHealth is pleased to announce the expansion of our partnership with QualDerm Partners! We plan to integrate our clinical research as a care option across QualDerm's 158 dermatological practices. We anticipate this partnership will broaden our patient reach and enable specialized care for patients with different dermatological conditions. Read more about our collaboration here: https://yhoo.it/3xMsVkZ #dermetology #skincare #esthiology #esthetician #clinicaltrials #cosmetics

Clinical trials have been at the forefront of discovering new microbiome therapies to prevent and reverse diseases. In a new article, Jim Cremins, MD, a strategic advisor for ObjectiveHealth and a career gastroenterologist, discusses the latest advancements in microbiome-based therapies and their applications in treating gastrointestinal conditions. https://lnkd.in/er8-pSqg #gastroenterology #clinicaltrials #microbiome

Bladder cancer ranks among the most common cancers worldwide. At diagnosis, 75% of patients have non-muscle-invasive bladder cancer, also known as superficial bladder cancer. Our team partners with individuals to advance the development of enhanced pharmaceuticals and therapeutic interventions for oncology patients. Learn more about our focus areas here: https://lnkd.in/gvvmVJFa

Yesterday, Rebecca Beatty Little, EVP of Clinical Strategy and Development at ObjectiveHealth, highlighted our technology's impact on clinical trials at the 2024 SCRS West conference. ObjectiveHealth technology solution here: https://lnkd.in/dYRwFumu #SCRSWest2024 #SCRSWest #clinicalresearchtools #clinicaltrials #clinicalresearchsoftware

Rebecca Beatty Little, EVP of Clinical Strategy and Development at ObjectiveHealth, will discuss our transformative technology at the 2024 SCRS West conference on June 3 and 4. We're excited to share our groundbreaking trial technology, matching patients to trials with precision. Can’t wait to see everyone in Arizona! #SCRSWest2024 #SCRSWest #clinicalresearchtools #clinicaltrials #clinicalresearchsoftware

We're excited to attend the 2024 SCRS West conference! Visit us at Booth #36 to learn more about how our technology is reshaping clinical trials. Looking forward to connecting with everyone! #SCRSWest2024 #SCRSWest #clinicalresearchtools #clinicaltrials #clinicalresearchsoftware

ObjectiveView is our sponsor portal offering access to recruitment and trial data through real-time EHR integration. It expedites patient identification and streamlines enrollment timelines. We'll be at the 2024 SCRS West conference to demo our technology. Learn more: https://lnkd.in/ggGKD9GE #SCRSWest2024 #SCRSWest #clinicalresearchtools #clinicaltrials #clinicalresearchsoftware